PB Fintech founders sell 1.1% stake via block deal

What happened and why the stock is in focus

PB Fintech Ltd, the parent of insurance brokerage platform Policybazaar, came into focus after reports and market data pointed to a founder stake sale through block and bulk deals. Co-founders Yashish Dahiya and Alok Bansal were expected to divest around 1.1% equity through a block deal. The proposed transaction size was pegged at about $106 million, which was also reported as roughly Rs 885 crore. The base price discussed in reports was Rs 1,800 per share, implying a discount of up to 2.2% to the previous close. A 90-day lock-in period for the sellers was also reported as part of the transaction structure. The news flow led to a decline in the stock, with the market tracking both the pricing and the identity of buyers.

Proposed block deal terms reported ahead of the trade

According to reports cited in the market, the deal involved the sale of 5.05 million shares. That share count equals 50.5 lakh shares and was described as about 1.1% of PB Fintech’s total outstanding equity. The base price was indicated at Rs 1,800 per share, framed as a discount to the then market price. The discount was reported at up to 2.2% compared to the previous closing level. The sale was positioned as a founder divestment by Yashish Dahiya and Alok Bansal. The reported deal size was about $106 million, or around Rs 885 crore. Reports also indicated a 90-day lock-in for the sellers, restricting further sales for three months.

What the exchange data showed after execution

Subsequent exchange data and deal reports indicated that the stake sale did take place through open market transactions. PB Fintech’s chief executive Yashish Dahiya and Vice Chairman Alok Bansal sold a total of 50.50 lakh shares, representing a 1.09% stake in the company. The combined transaction value was reported at Rs 919.86 crore, executed at an average price of Rs 1,821.50 per share. Within the split, Dahiya offloaded 34 lakh shares in two tranches, amounting to a 0.74% stake. Bansal sold 16.50 lakh shares, equivalent to a 0.36% holding, as per block deal data references. Reports also stated that as many as 50.5 lakh shares changed hands in the pre-open block deal window.

Details of pricing, discount and lock-in

While the base price discussed ahead of the trade was Rs 1,800 per share, the execution price widely reported was Rs 1,821.50 per share. That price was described as being at around a 1% discount to the previous closing price of Rs 1,839.75. Reports also said official details of the transaction had not been confirmed at the time of publication. Separate references pegged the transaction value at around Rs 920 crore and also cited approximately Rs 960 crore in parts of the reporting. The lock-in clause was consistently mentioned as a 90-day lock-in for the sellers. This lock-in typically signals that sellers will not return to the market with additional shares in the near term. The key market variable remained how investors interpret founder selling alongside ongoing business investments.

Share price reaction on BSE and NSE

PB Fintech shares ended at Rs 1,839.75 on the BSE, down 1.43% following the news of the block deal. Another data point in the same coverage described the close as 1.4% lower at Rs 1,839.75. After the development, the stock slipped 1.1% to hit an intraday low of Rs 1,819.80 on the BSE, as per the report. In Thursday trade coverage, PB Fintech shares were quoted 0.27% lower at Rs 1,834.90 on the NSE. Deal data also mentioned 50,50,000 shares valuing Rs 919.86 crore changing hands via block deals. The pricing, volumes and discounts became the key factors for traders assessing near-term sentiment.

How founder holdings changed after the stake sale

Post the sale, Dahiya’s holding in PB Fintech declined to 3.57% from 4.31%, according to the reported figures. Bansal’s stake fell to 1.04% from 1.40%. These disclosures clarified that the transaction was a partial divestment and not a complete exit. The reduced holdings still keep both founders meaningfully invested in the company. At the same time, changes in promoter or founder ownership are closely watched in consumer internet and fintech names because they can influence perception around alignment. The market generally distinguishes between planned liquidity events and sales driven by business concerns, and the coverage here framed it as a block deal with a lock-in.

Who bought the shares, as per reports

Some reports said the shares were picked up by global institutions such as Goldman Sachs, Morgan Stanley and Societe Generale. Domestic mutual funds were also named, including ICICI and Tata Mutual Funds, along with Citigroup. However, another part of the reporting stated that buyers and sellers were not officially known. Given that inconsistency, the clean takeaway is that the transaction was treated as institution-led, with multiple large financial names mentioned in market chatter, while official counterparty details were not confirmed in the cited coverage. For investors, the presence of large institutions in the reported buyer list can matter because it often signals depth of demand at the negotiated price point.

Board approves Rs 696 crore infusion into PB Healthcare subsidiary

Separately, PB Fintech said it proposes to infuse Rs 696 crore in its subsidiary PB Healthcare Services Private Limited in the next financial year to grow its business. The decision was taken by the Board of Directors in a meeting held on Tuesday, as per a regulatory filing. The board approved an aggregate investment of up to Rs 696 crore in PB Healthcare Services Private Limited, a wholly owned subsidiary. The infusion is planned through subscribing or purchasing shares or Compulsory Convertible Preference Shares during FY 2025-26. The company said the investment is subject to shareholder approval through postal ballot. It also said the investment will be made along with other external investors in PB Healthcare Services Private Limited.

Key numbers at a glance

Market context around the transaction

The reporting also noted that PB Fintech stock had surged 38.62% over the past one year. That backdrop matters because secondary sales often follow periods of price appreciation and higher liquidity. In this case, the deal was structured with a discount to market and a 90-day lock-in, both common features in such transactions. Alongside the stake sale headlines, the board-approved capital infusion into PB Healthcare adds a parallel narrative about investment and expansion plans. Investors typically assess how these moves fit together: founder liquidity on one hand, and fresh capital deployment into a subsidiary on the other. The immediate market reaction was modestly negative, reflected in the close at Rs 1,839.75 and the intraday dip to Rs 1,819.80.

Conclusion

PB Fintech’s founder-led sale of about 1.09% stake, valued at around Rs 919.86 crore at an average reported price of Rs 1,821.50 per share, kept the counter active amid block deal tracking. The company’s planned Rs 696 crore investment into PB Healthcare Services in FY 2025-26, subject to shareholder approval via postal ballot, is the next formal milestone flagged in disclosures.